Live Breaking News & Updates on Total Functional Capacity

Stay updated with breaking news from Total functional capacity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity


Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity
Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington s Disease.
Exploratory additional efficacy data show pridopidine (45 mg bid) to be the first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity (TFC).
Results from the Open-HART trial demonstrate the potential durability of the effect of pridopidine with less TFC decline over 5 years compared to the historical placebo group, as well as positive safety and tolerability data.
Prilenia Therapeutics B.V., a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of two articles in the peer-reviewed journal, ....

Andrew-mcgarry , Ralf-reilmann , Michaelr-hayden , Emily-henderson , George-huntington-institute , Healey-center , Clinical-development , Total-functional-capacity , Amyotrophic-lateral-sclerosis , Functional-capacity , Early-stage-participants

Additional analyses of pridopidine for HD


 E-Mail
Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in peer-reviewed journal, The Journal of Huntington s Disease.
Exploratory additional efficacy data show pridopidine (45 mg bid) to be the first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity (TFC).
Results from Open-HART trial demonstrate potential durability of the effect of pridopidine with less TFC decline over 5 years compared to historical placebo group, as well as positive safety and tolerability data.
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of two articles in the peer-reviewed journal, ....

Naarden , Noord-holland , Netherlands , Boston , Massachusetts , United-states , Herzliya , Tel-aviv , Israel , Melanie-toyne-sewell , Limor-ben-har , Michael-hayden